Figure 1

Clinical responses to PPV. a, b) Computed tomography findings of a PR case with mrTNBC (case 2 in Table S2) before and after the 12th vaccination. A 63-year-old woman with a recurrent lung mass underwent 12 vaccinations in combination with gemcitabine (1,000 mg/m²/week for three weeks followed by one week intermission). At four months after the first vaccination, the lung mass was remarkably reduced in size (arrow). c, d) Computed tomography findings of a SD case with mrTNBC (case 18 in Table S2) before and after the eighth vaccination. A 34-year-old woman with a recurrent lung mass underwent eight vaccinations in combination with two cycles of eribulin mesylate (1.4 mg/m²/week for two weeks followed by one week intermission). At three months after the first vaccination, the lung mass was slightly decreased in size (arrow). mrTNBC, metastatic recurrent triple negative breast cancer; PPV, personalized peptide vaccination; PR, partial response; SD, stable disease.